A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

Exclusion Criteria

• •History of any clinically important disease or disorder which may put the participant at risk because of participation in the study or influence the results.
• •Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV).
• •Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
• •History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to metformin or AZD0780.
• •Treatment with any lipid lowering therapy or AZD0780 within the 3 months prior to the Screening Visit.
• •Treatment with drugs for reduction or inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) within the last 12 months prior to the Screening Visit (approved or investigational and apart from AZD0780).
• •Current or previous administration of inclisiran.